Kazia Therapeutics (KZIA) Debt Ratio (2011 - 2025)

Kazia Therapeutics (KZIA) posted Debt Ratio of 0.2 for Q4 2025, down 61.64% on a QoQ basis from 0.52 in Q2 2025, and up 77.01% year-over-year from 0.11 in Q4 2024.

Kazia Therapeutics (KZIA) has 6 years of Debt Ratio data on file, last reported at 0.2 in Q4 2025.

  • In Q4 2025, Debt Ratio rose 77.01% year-over-year to 0.2; the TTM figure through Dec 2025 stood at 0.2 (up 77.01% YoY), while the FY2025 annual figure was 0.52, up 73.23% from the prior year.
  • Debt Ratio retreated to 0.2 in Q4 2025, from 0.52 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.52 in Q2 2025 and bottomed at 0.05 in Q2 2022.
  • A 4-year average of 0.25 and a median of 0.3 in 2024 frame the typical range for Debt Ratio.
  • Annual changes were most pronounced in 2023 — Debt Ratio soared 666.25% — and 2024, when it plunged 68.06%.
  • Year by year, Debt Ratio stood at 0.05 in 2022, then surged by 752.28% to 0.35 in 2023, then plunged by 68.06% to 0.11 in 2024, then surged by 77.01% to 0.2 in 2025.
  • The last three Debt Ratio figures came in at 0.2 (Q4 2025), 0.52 (Q2 2025), and 0.11 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.18
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 1.41
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.05
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Kazia Therapeutics 1.55 Bn 1.55 Bn - 0.20

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 0.20
Jun 30, 2025 0.52
Dec 31, 2024 0.11
Jun 30, 2024 0.30
Dec 31, 2023 0.35
Jun 30, 2023 0.31
Jun 30, 2022 -0.05
Jun 30, 2018 0.00
Jun 30, 2011 0.08